Aurinia Pharmaceuticals Inc. Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Aurinia Pharmaceuticals Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2026-06-30 was $363.00K, a 9.48% decline year-over-year.
- Aurinia Pharmaceuticals Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-06-30 was $401.00K, a 42.96% decline year-over-year.
- Aurinia Pharmaceuticals Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2024-12-31 was $381.00K, a 59.64% decline year-over-year.
- Aurinia Pharmaceuticals Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2024-09-30 was $0.00.
- Aurinia Pharmaceuticals Inc. stock issued during period, value, employee stock purchase plan for fiscal 2025 was $756.00K, a 30.26% decline from fiscal 2024.
- Aurinia Pharmaceuticals Inc. stock issued during period, value, employee stock purchase plan for fiscal 2024 was $1.08M, a 41.41% decline from fiscal 2023.
- Aurinia Pharmaceuticals Inc. stock issued during period, value, employee stock purchase plan for fiscal 2023 was $1.85M, a 3.24% decline from fiscal 2022.
- Aurinia Pharmaceuticals Inc. stock issued during period, value, employee stock purchase plan for fiscal 2022 was $1.91M, a 226.84% increase from fiscal 2021.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2026-06-30 | $363.00K 10-Q · filed 2026-08-06 | |
| 2025-12-31 | $756.00K 10-K · filed 2026-02-26 | |
| 2025-06-30 | $401.00K 10-Q · filed 2026-08-06 | |
| 2024-12-31 | $381.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.08M 10-K · filed 2026-02-26 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $15.02M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $703.00K 10-Q · filed 2025-11-04 | $15.02M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $13.37M 10-Q · filed 2024-05-02 | $15.22M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $944.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.85M 10-K · filed 2026-02-26 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | |
| 2023-06-30 | $906.00K 10-Q · filed 2024-08-01 | |
| 2022-12-31 | $689.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $1.91M 10-K · filed 2025-02-27 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | |
| 2022-06-30 | $1.22M 10-Q · filed 2023-08-03 | |
| 2021-12-31 | $585.00K 10-K · filed 2024-02-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B |